Reduced levels of omentin-1 are associated with poor prognosis in CVD and endothelial dysfunction in overweight patients, and elevated levels of omentin-1 are associated with improved endothelial function in patients with T2D and with increased insulin sensitivity and reduced BMI, blood pressure, and IL-6 and CRP-1 levels in patients without T2D [113]. This evidence concerns the gene INS and type 2 diabetes mellitus.